Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (15978)	8/14/2002 11:49:14 PM
From: aknahow	Respond to of 17367

Thanks, Cacaito, your explanation seems logical to me. "..the subjects are going to Antegren research by Elan/Biogen a better drug with good results in phase II (a real phase II, by the way, it had about 200 subjects with several dosing regimes and double blind ramdomized placebo control group and statistical significance achieved) researchers and subjects know that, why go to an open label small trials without any clinical basis (theoretical basis, yes)and little money available."